welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer jumps on 7-year-old data
Acer Therapeutics Inc. had a welcoming first week on the Nasdaq stock exchange, seeing shares sruge more 10% Monday after verifying positive clinical results published almost seven years ago from a study of celiprolol, the active ingredient in its lead drug candidate.
The study tested celiprolol against placebo in patients with vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening disorder that causes arteries and organs to easily rupture. After receiving treatment for about four years on average, 20% of the participants in the investigational arm experienced arterial events versus 50% of those in the control arm.
expertly curated content related to this topic
-
If You Can’t Connect the Issues, Think Connective Tissues (Heidi Collins, MD)https://www.youtube.com/watch?v=H0jaF6Rn...
-
21st Century Ehlers-Danlos Syndrome (EDS) Sourcebook: Clinical Data for Patients, Families, and Physicians – C...This comprehensive ebook provides author...
-
Sunshine and SpoonsI'm Hannah, a mom of four who loves Jesu...
-
The Ehlers–Danlos Syndromes, Rare TypesThe Ehlers–Danlos syndromes comprise a...
-
Ehlers-Danlos Society Receives Transformational Gift to Accelerate Genomic Research into Hypermobile EDSThe Ehlers-Danlos Society has announced ...